An observational, prospective study conducted in Italy has shed light on the effectiveness of intranasal mometasone furoate as a treatment for non-allergic rhinitis (NAR). Treatment with 200 µg twice a day mometasone furoate for fifteen consecutive days per month for six consecutive months, along with isotonic nasal saline, remarkably enhanced olfactory function and quality of life (QoL) in an Italian population of patients with NAR and NAR with neutrophils as the most frequent cytological pattern.

In this real-life study, researchers aimed to evaluate the impact of mometasone furoate on 31 patients (between the ages of 18 and 64 years) suffering from NAR. They received intranasal mometasone furoate at a dosage of 200 µg twice a day for fifteen consecutive days per month over a span of six consecutive months. In addition to mometasone furoate, participants were also administered isotonic nasal saline. Several key parameters were evaluated both at the study's outset and after the treatment period. These parameters included:

1. Cytologic pattern of local inflammation: Researchers observed the cytologic patterns of local inflammation.
2. Nasal airflow: Peak nasal inspiratory flow (PNIF) was used to assess nasal airflow.
3. QoL: It was measured using the the short-form 36-item health survey (SF-36v2), the sinonasal outcome test (SNOT-22), and the rhinitis quality of life questionnaire (RQLQ).
4. Combined Symptom Medication Score (CSMS): The CSMS was utilized to gauge symptom severity.
5. Olfactory function: The Sniffin’ sticks-16 identification test (SSIT-16) was employed to examine olfactory function.

The study identified that NAR with neutrophils was the most predominant cytological pattern, affecting 48% of the total sample. Importantly, the therapeutic response to intranasal mometasone furoate was positive. Patients experienced an improvement in their olfactory function and reported an overall enhancement in their quality of life.

In conclusion, this study underscores the effectiveness of intranasal mometasone furoate as a treatment option for patients suffering from NAR. These findings provide valuable insights into the management of NAR and offer a promising avenue for improving the lives of individuals affected by this condition. Further research and clinical studies may help refine the treatment approaches for NAR, ultimately benefiting patients with this condition.